Blue Ocean Strategy of A Defense of Direct-to-Consumer Prescription Drug Advertising

Introduction

The blue ocean strategy refers to a situation or a market where there is no irrelevant competition, or where there is negligible competition. The blue ocean strategy of A Defense of Direct-to-Consumer Prescription Drug Advertising is focused on searching for new markets and business avenues which operate with minimal pricing pressures. The blue ocean strategy can be applied across different sectors and industries, and the businesses that exist within them. A Defense of Direct-to-Consumer Prescription Drug Advertising blue ocean strategy is pivoted on entering new market spaces, or developing them as well as on innovation focused internally or externally that helps reinvent the industry to ensure no irrelevant competition (Kim & Mauborgne, 2014).

Moving away from saturated markets

The A Defense of Direct-to-Consumer Prescription Drug Advertising continues to operate in saturated market spaces, and is restricted in growth and expansion. The A Defense of Direct-to-Consumer Prescription Drug Advertising’s businesses often face hurdles in the way of development and are also faced with increasingly intense pricing pressures- and are thus said to operate in a red ocean. A red ocean is marked with cut-throat competition and pricing wars that compromise the profits for all players. Pressures in saturated markets along with narrow growth spaces had forced the A Defense of Direct-to-Consumer Prescription Drug Advertising to search for new avenues – vertically or horizontally – to be able to enjoy higher market shares, and swim in blue oceans (Kim & Mauborgne, 2014).

Blue ocean strategy and differentiation

New industry boundaries

As companies and organizations move towards blue oceans, they redraw and redesign industry boundaries. This is possible through innovation and creativity. The A Defense of Direct-to-Consumer Prescription Drug Advertising also explores new platforms and channels, as well as means of doing business and is thus able to expand existing industry boundaries. The A Defense of Direct-to-Consumer Prescription Drug Advertising has also been able to show the potential of developing new industries through its innovations – by identifying new spaces and making the competition irrelevant (Agnihotri, 2016).

Differentiation

The A Defense of Direct-to-Consumer Prescription Drug Advertising has focused on differentiation under the blue ocean strategy. The A Defense of Direct-to-Consumer Prescription Drug Advertising’s efforts towards differentiation are focused on creating unique value for the customers in its product and service offerings (Agnihotri, 2016; Blue Ocean Strategy, 2022).

Cost efficiencies and low cost

Under blue oceans, the A Defense of Direct-to-Consumer Prescription Drug Advertising also focuses on maintaining affordability for the value additions and differentiated products and services that it offers. The A Defense of Direct-to-Consumer Prescription Drug Advertising commonly continuously reevaluates and reassesses its own processes and systems to maintain high-cost efficiencies (Freedman, 2022).

Value innovation – value addition and low-cost maintenance

In doing so, the A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to explore blue oceans through value additions as well as affordability for consumers. The A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to successfully identify what consumer’s value and include it in its offerings and value propositions. At the same time, the A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to provide the value differentiation at affordable costs. In this manner, the A Defense of Direct-to-Consumer Prescription Drug Advertising enjoys high levels of value innovation (Kim, 2002; Kim & Mauborgne, 2014).

Understanding red oceans

Under red oceans, where the A Defense of Direct-to-Consumer Prescription Drug Advertising previously operated, all layers had accepted the predefined structures and boundaries of the industry, and had continued to operate as well as compete within these (The Economic Times, 2022).

Cut throat competition

To be able to remain profitable and successful, players, including the A Defense of Direct-to-Consumer Prescription Drug Advertising within red oceans, focused efforts on developing and maintaining competitive advantages over one another, and other players. This advantage was largely cost-based, as in the case of the A Defense of Direct-to-Consumer Prescription Drug Advertising. In this way, wealth was only redistributed at the expense of other players, and the A Defense of Direct-to-Consumer Prescription Drug Advertising failed to create any new wealth in the red oceans (Kim & Mauborgne, 2005).

Understanding blue oceans

Under the blue ocean strategy, the A Defense of Direct-to-Consumer Prescription Drug Advertising operates in an industry and market space that is not marked with set boundaries or structures. These blue ocean structures have been recreated by the A Defense of Direct-to-Consumer Prescription Drug Advertising at large, as well as by other players. Other players have also contributed to the restructuring of the industry through innovation (Kim & Mauborgne, 2014).

Restructuring industrial boundaries under the blue ocean strategy

Under the blue ocean strategy, the A Defense of Direct-to-Consumer Prescription Drug Advertising is not restricted by predefined rules, barriers, and principles. Instead, the A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to shift its strategic direction and attention from focusing on supply towards working on developing and creating demand (Blue Ocean Strategy, 2022). The A Defense of Direct-to-Consumer Prescription Drug Advertising, in this manner, is focused on the building of value innovation in its offerings, along with ensuring efforts towards building and maintaining differentiation and cost-effectiveness. In this way, the A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to immaterialize the competition (Kim & Mauborgne, 2017).

Strategic directions for blue oceans

The A Defense of Direct-to-Consumer Prescription Drug Advertising has four different strategic directions, which it can choose from four continuing to pursue its blue ocean strategy. All of these strategic directions will strengthen the company’s current business position and will supports its strategy of value addition and cost efficiencies, as well as differentiation – allowing it to develop strong and sustainable market positions. These directions are

Raise

• The A Defense of Direct-to-Consumer Prescription Drug Advertising should assess and evaluate the current industry standards and practices.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising should identify loopholes, and areas which can be improved, expanded upon, or developed a new within the industry.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising should identify different drivers and factors within the industry boundaries.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising should identify through research and observation the different factors that could raise above the existing industry standards (Kim, 2002; Kim & Mauborgne, 2017).

Eliminate

• The A Defense of Direct-to-Consumer Prescription Drug Advertising should assess and observe current industry standards.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising should observe players’ practices within the industry, and relate the same with the industry standards.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising can identify the standards which are not needed, which are obsolete, and which may slow down operations and processes.

• These standards can be eliminated in own operations by the A Defense of Direct-to-Consumer Prescription Drug Advertising (Kim & Mauborgne, 2014; Freedman, 2022).

Reduce

• The A Defense of Direct-to-Consumer Prescription Drug Advertising can also assess an observe industry standards for identifying factors that are not needed, or needed partially.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising can work on reducing these standards to enhance operational performance and maximum utilization of resources as well as value addition (The Economic Times, 2022; Kim & Mauborgne, 2014).

Created

• The A Defense of Direct-to-Consumer Prescription Drug Advertising can also expand current industry boundaries and standards.

• This expansion will be possible by the A Defense of Direct-to-Consumer Prescription Drug Advertising through expanding and creating new standards.

• The new standards can be created by the A Defense of Direct-to-Consumer Prescription Drug Advertising through observing industry processes and operations, and identifying potential loopholes.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising can introduce new processes and standards to redesign industry boundaries (Agnihotri, 2016; Kim & Mauborgne, 2005).

Blue ocean strategy: organizational competencies

The A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to successfully implement the blue ocean strategy because of three important organizational elements (Freedman, 2022). These organizational elements have allowed the A Defense of Direct-to-Consumer Prescription Drug Advertising to explore blue oceans, experiment successfully with innovation, and add value to its product offerings. These elements include the following:

Mindset

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has a progressive mindset that is rooted in this participative and visionary leadership (Bratton, 2020).

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has a positive and can-do attitude and mindset.

• This mindset has allowed the A Defense of Direct-to-Consumer Prescription Drug Advertising to achieve success through high focus and efforts (Wilson, 2018).

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has high motivation levels of employees – which enhances the optimal performance of the organization and has allowed it to explore Blue Ocean through creativity (Kim & Mauborgne, 2017; Kim & Mauborgne, 2005; Wilson, 2018).

Tools

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has access to multiple resources that has allowed it to take advantage of the blue ocean strategy (Mebert & Lowe, 2017).

• These resources A Defense of Direct-to-Consumer Prescription Drug Advertising capabilities are internal as well as external for the A Defense of Direct-to-Consumer Prescription Drug Advertising.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has also invested resources and trainings for developing internal capabilities and capacities for ensuring upgraded skills and increased value addition (Buchanan & Huczynski, 2019; Chernev, 2018).

Culture

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has a learning culture, and encourages all employees to ask questions and carry out healthy discussions (Anthony, 2021; Schein, 2010).

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has a culture that is focused on research and development, which in turn leads to new innovations and solutions for existing demands and challenges (Wunder, 2019).

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has an inclusive and diverse culture, which leads to increased synergies that allow the development and implementation of blue ocean strategies easily (Wilson, 2018).

Using the blue ocean strategy effectively: steps for successful implementation

The A Defense of Direct-to-Consumer Prescription Drug Advertising has developed the blue ocean strategy following systematic and organized processes and steps (Kim & Mauborgne, 2017). The steps that the A Defense of Direct-to-Consumer Prescription Drug Advertising undertook for developing the blue ocean strategy include:

Step1

The A Defense of Direct-to-Consumer Prescription Drug Advertising conducted thorough market and industry research to identify the right place to work towards developing a core team (Kim & Mauborgne, 2014; Freedman, 2022). This core team was responsible for driving A Defense of Direct-to-Consumer Prescription Drug Advertising forward strategically towards new value additions and differentiations (Blue Ocean Strategy, 2022; Kim & Mauborgne, 2017 b).

Step2

The A Defense of Direct-to-Consumer Prescription Drug Advertising continued to conduct deep market analysis as well as studied and assessed the competition closely. This was needed by the A Defense of Direct-to-Consumer Prescription Drug Advertising to identify potential opportunities, and demand gaps in the existing industry as well as potential structural changes in the existing industrial boundaries (Blue Ocean Strategy, 2022).

Step3

The A Defense of Direct-to-Consumer Prescription Drug Advertising’s assessment of the macro environment, and the market spaces allowed it to also identify the challenges and issues hidden in the current industry structure and design (Machado, 2019; Kim & Mauborgne, 2017 b). These issues and problems have restricted the industry size, and led to restrictive growth for the A Defense of Direct-to-Consumer Prescription Drug Advertising. The A Defense of Direct-to-Consumer Prescription Drug Advertising was also blue to identify new non-customers in this assessment- which could be turned into future consumers (Blue Ocean Strategy, 2022).

Step4

The A Defense of Direct-to-Consumer Prescription Drug Advertising worked to redesign and reconstruct the industry boundaries and structures in a systematic manner. This was done through identifying new opportunities, as well as through exploring new innovations and valuations in existing offerings (Blue Ocean Strategy, 2022).

Step5

The A Defense of Direct-to-Consumer Prescription Drug Advertising finally elected the right blue ocean move, i.e. conducted various pilot testing’s and market testing for its new offerings before finalizing and launching them in the market to attract new consumers, and explore new markets (Blue Ocean Strategy, 2022).

Tackling challenges on the way to Blue Ocean

Restructuring and reorganizing the boundaries and structures of the industries is not that simple (Anthony, 2021; Kim & Mauborgne, 2017 b). Managers and practitioners of the A Defense of Direct-to-Consumer Prescription Drug Advertising seek to renew the value of their offerings within the organization – mostly using new technologies and advances networks to not only create value propositions, but also transform existing ones (Kim & Mauborgne, 2005; Kim, 2002). However, the A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to overcome resistance towards change and innovation within the organization, as well as in the external environments, because of:

Organizational culture

The culture within the A Defense of Direct-to-Consumer Prescription Drug Advertising supports exploration and innovation. This culture is important for supporting the development and implementation of new ideas that boost the value propositions of the A Defense of Direct-to-Consumer Prescription Drug Advertising (Chernev, 2018; Bratton, 2020; Martinez, Beaulieu, & Gibbons, 2015).

Business design

The A Defense of Direct-to-Consumer Prescription Drug Advertising also continually practices business design (Freedman, 2022). The A Defense of Direct-to-Consumer Prescription Drug Advertising ensures that it’s leading from the font. This means that the A Defense of Direct-to-Consumer Prescription Drug Advertising ensures that its teams are empowered, and confident in tackling ambiguous and difficult challenges and issues. This allows the A Defense of Direct-to-Consumer Prescription Drug Advertising to identify new opportunities and innovate (Wunder, 2019).

Strong and visionary leadership

The A Defense of Direct-to-Consumer Prescription Drug Advertising has a forward-thinking, progressive, charismatic leadership. This leadership ensures that the A Defense of Direct-to-Consumer Prescription Drug Advertising continually engages in disruptive processes and innovations – which in turn allow the company to explore and implement the blue ocean strategy. The leadership is supportive of, and facilitates the change processes within the company (Machado, 2019).

Communication

The A Defense of Direct-to-Consumer Prescription Drug Advertising ensures that all communication within the organization is transparent and quick (Chernev, 2018; Buchanan & Huczynski, 2019). The leadership and management levels have frequent meetings within the company along managerial levels (Wilson, 2018; Wunder, 2019). This allows employees to feel on board of the happenings, and be part of a change from the beginning – understanding its need and facilitating its implementation. This is critical for ensuring successful innovation and adoption of the blue ocean strategy (Anthony, 2021; Chernev, 2018; Kim, 2002).

Value innovation in blue ocean strategy

Value innovation within the blue ocean strategy focuses on value as well as innovation (Blue Ocean Strategy, 2022; Kim & Mauborgne, 2017). This means that the A Defense of Direct-to-Consumer Prescription Drug Advertising seeks to innovate and create value at the same time as a means of differentiation within the marketplace to be able to implement the blue ocean strategy (Kim & Mauborgne, 2014). The A Defense of Direct-to-Consumer Prescription Drug Advertising does not only engage in value creation – which focuses on scaling the existing value only instead of creating a new one (Blue Ocean Strategy, 2022; Agnihotri, 2016; Kim & Mauborgne, 2014).

Technology innovation

The A Defense of Direct-to-Consumer Prescription Drug Advertising engages in value innovation through technology innovation. The A Defense of Direct-to-Consumer Prescription Drug Advertising ensures that it uses advanced and progressive technology to address various consumer demands and problems as well as needs in innovative ways and manners (Kim & Mauborgne, 2005). However, the A Defense of Direct-to-Consumer Prescription Drug Advertising ensures that it focuses on value innovation rather than technology innovation in its value propositions so that new value through technology is created for consumers (Kim, 2002; Wilson, 2018).

Low cost

The A Defense of Direct-to-Consumer Prescription Drug Advertising also ensures affordability with value innovation. The value innovation allows the A Defense of Direct-to-Consumer Prescription Drug Advertising to operate at low costs, and maintain cost efficiencies (Chernev, 2018). As a result, the A Defense of Direct-to-Consumer Prescription Drug Advertising maintains low costs and high value for consumers – allowing it to tap into new consumer groups as well. As a result, the A Defense of Direct-to-Consumer Prescription Drug Advertising is able to enjoy a high growth rate as well as increased sales and profits (Kim & Mauborgne, 2014).

The strategies and strategic directions for designing and implementing the blue ocean strategy have been overseen through some guiding and fundamental principles by the A Defense of Direct-to-Consumer Prescription Drug Advertising. These include”

Formulation principles

Redesigning the industry

• The A Defense of Direct-to-Consumer Prescription Drug Advertising sought to reconstruct, redesign and rebuild the market boundaries and standards.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising was bold enough to redefine the industry space and the market space in which it operated (Mebert & Lowe, 2017).

Long term focus

• The A Defense of Direct-to-Consumer Prescription Drug Advertising focused on long-term success and sustainability, instead of short-term gains and numbers.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising was visionary, and aw beyond the existent customer demand and needs (Freedman, 2022).

Demand creation

• The A Defense of Direct-to-Consumer Prescription Drug Advertising creates demand for the new value-added offerings it manufactured and proposed in the blue oceans (Kim, 2002).

• The A Defense of Direct-to-Consumer Prescription Drug Advertising tapped into new customer groups and target audiences (Kim & Mauborgne, Red Ocean Traps (Harvard Business Review Classics), 2017 b).

Execution principles

Overcoming organizational challenges

Organizational culture

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has a result organizational culture (Martinez, Beaulieu, & Gibbons, 2015; Schein, 2010).

• The A Defense of Direct-to-Consumer Prescription Drug Advertising invests in research and development.

• The A Defense of Direct-to-Consumer Prescription Drug Advertising is quick to adapt to change and has a disciplined change management team to oversee change processes (Chernev, 2018; Kim & Mauborgne, 2014).

Environmental assessment

• The A Defense of Direct-to-Consumer Prescription Drug Advertising continually assesses its internal and external environments and creates contingency plans (Chernev, 2018; Machado, 2019).

• The A Defense of Direct-to-Consumer Prescription Drug Advertising engages in pre-strategic planning to help strengthen its strategic focus and direction (Wilson, 2018; Kim & Mauborgne, 2017 b).

Leadership

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has a visionary leadership (Bratton, 2020).

• The leadership at the A Defense of Direct-to-Consumer Prescription Drug Advertising has a participative approach which encourages employee motivation and their organizational commitment.

• The leadership ensures optimal organizational performance at the A Defense of Direct-to-Consumer Prescription Drug Advertising (Freedman, 2022; Kim & Mauborgne, 2005).

Developing execution strategy

• The A Defense of Direct-to-Consumer Prescription Drug Advertising has developed a sequential strategic direction for execution.

• The execution of the blue ocean strategy is based on market research (Anthony, 2021).

• The execution of the blue ocean strategy has been carefully planned to ensure that it’s timely.

• The execution involves all parts and members of the A Defense of Direct-to-Consumer Prescription Drug Advertising (The Economic Times, 2022; Kim, 2002).

Blue ocean strategic Tools

The A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to use multiple operational and strategic tools.

Shift in organizational mindset

These tools kits have been important for the A Defense of Direct-to-Consumer Prescription Drug Advertising in helping it develop the right mindset needed for aligning processes and systems towards the blue ocean strategic direction (Kim & Mauborgne, 2017 b). The tools have been a powerful source for the A Defense of Direct-to-Consumer Prescription Drug Advertising in facilitating it towards aligning its resources, and identifying potential blue oceans (Kim, 2002). The A Defense of Direct-to-Consumer Prescription Drug Advertising has been diligent in ensuring that its teams and organizational members are familiar with the blue can strategies and tools so that the shift in their mindset is facilitated and strengthened (Wunder, 2019).

Cultural driver

Moreover, the tools also ensure increased alignment of the A Defense of Direct-to-Consumer Prescription Drug Advertising’s culture with the strategy. This, in turn, has allowed the A Defense of Direct-to-Consumer Prescription Drug Advertising to realize the increased number of opportunities, and embed creativity in its internal processes and systems (Kim, 2002; Buchanan & Huczynski, 2019).

These tools include, for example:

• Value innovation

• Six path framework

• Strategy canvas

• Four action framework

• Tipping point leadership

• ERRC Grid

• Pioneer settler migrator map

• Buyer utility map

• 3 tiers of non-customers

• Fair processes

• Visualizing strategy (The Economic Times, 2022)

Conclusion

With the use of the blue ocean strategy, the A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to redesign the industrial boundaries and standards using multiple techniques and tools that have been identified and discussed briefly in this paper.

The blue ocean strategy has been an important strategic element for the A Defense of Direct-to-Consumer Prescription Drug Advertising. The A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to explore new markets and tap into new customer groups through using the blue ocean strategy. This has been possible for the A Defense of Direct-to-Consumer Prescription Drug Advertising through continuous investment in research and development as well as through its organizational cultural, which is focused on innovation and creativity. The A Defense of Direct-to-Consumer Prescription Drug Advertising has been able to make use of innovative processes and progressive technology to create value innovation. At the same time, the A Defense of Direct-to-Consumer Prescription Drug Advertising has moved out of red oceans and no longer competes over pricing strategies. This has also allowed A Defense of Direct-to-Consumer Prescription Drug Advertising to build a cost advantage, and maintain affordability in its offerings for customers.

References

Agnihotri, A. (2016). Extending boundaries of blue ocean strategy. Journal of Strategic Marketing, 24 (6), 519-528.

Anthony, H. (2021). Understanding strategic management. New York: Oxford University Press.

Blue Ocean Strategy. (2022). WHAT IS BLUE OCEAN STRATEGY? Retrieved 2022, from Blue Ocean Strategy: https://www.blueoceanstrategy.com/what-is-blue-ocean-strategy/

Bratton, J. (2020). Organizational leadership. Newcastle upon Tyne: Sage.

Buchanan, D., & Huczynski, A. (2019). Organizational behaviour. London: Pearson UK.

Chernev, A. (2018). Strategic marketing management. Berlin/Heidelberg: Cerebellum Press.

Freedman, M. (2022). Blue Ocean Strategy: Creating Your Own Market . Retrieved 2022, from https://www.businessnewsdaily.com/5647-blue-ocean-strategy.html

Kim, W. (2002). Blue ocean strategy: from theory to practice. California management review, 47 (3), 105-121.

Kim, W., & Mauborgne, R. (2005). Value innovation: a leap into the blue ocean. Journal of business strategy .

Kim, W., & Mauborgne, R. (2014). Blue ocean strategy, expanded edition: How to create uncontested market space and make the competition irrelevant. Boston, Massachusetts: Harvard business review Press.

Kim, W., & Mauborgne, R. (2017 b). Red Ocean Traps (Harvard Business Review Classics). Boston, Massachusetts: Harvard Business Review Press.

Kim, W., & Mauborgne, R. (2017). Blue ocean leadership (Harvard business review classics). Boston, Massachusetts, United States: Harvard Business Review Press.

Machado, C. (2019). Organizational Behaviour and Human Resource Management. Berlin: Springer.

Martinez, E., Beaulieu, N., & Gibbons, R. (2015). Organizational culture and performance. American economic review, 105 (5), 331-35.

Mebert, A., & Lowe, S. (2017). Blue Ocean Strategy. Literary Criticism.

Schein, E. (2010). Organizational culture and leadership. Hoboken, New Jersey: John Wiley & Sons.

The Economic Times. (2022). What is 'Blue Ocean Strategy' . Retrieved 2022, from https://economictimes.indiatimes.com/definition/blue-ocean-strategy

Wilson, F. (2018). Organizational behaviour and work: a critical introduction. New York: Oxford university press.

Wunder, T. (2019). Rethinking strategic management: Sustainable strategizing for positive impact. Berlin: Springer Nature.